EUBIOLOGICS CO., LTD.

Highlights EuBiologics Co., Ltd.

Equities

A206650

KR7206650004

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-27 EDT			5-day change	1st Jan Change
12,360 ^KRW	+1.73%		+0.16%	+7.76%

01-29	Zimbabwe launches door-to-door cholera vaccination campaign	RE
2023	Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial	23-07-14	CI
EuBiologics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Eubiologics Co., Ltd. Announces Phase Iii Clinical Trial Ind Approval of Eucorvac-19, Covid-19 Vaccine Candidate, in South Korea	22-02-03	CI
EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea	21-01-21	CI
Global Health Investment Fund I, LLC, managed by Global Health Investment Advisors, LLC acquired 6.19% stake in EuBiologics Co., Ltd..	17-02-01	CI
EuBiologics Co., Ltd. has completed an IPO in the amount of KRW 19.2 billion.	17-01-19	CI
EuBiologics Co., Ltd. has filed an IPO.	16-09-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer